Alector, Inc. Common Stock (ALEC) Stock Price
ALECStock
$1.84−42.86%52W
Market Cap$205.45M
P/E—
PEG Ratio—
Div yield—
Beta0.64
ALEC Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-33.56%
Price vs S&P 500 (4W)-3.34%
VGM Score38.11
ALEC Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.23 | -$0.21 | +8.03%(+$0.02) | |
| Q1 2026 | -$0.28 | -$0.21 | +24.23%(+$0.07) | |
| Q4 2025 | -$0.36 | -$0.34 | +6.42%(+$0.02) | |
| Q3 2025 | -$0.41 | -$0.34 | +17.65%(+$0.07) | |
| Q2 2025 | -$0.47 | -$0.30 | +36.17%(+$0.17) |
ALEC Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.64
3.64
3.64
3.64
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
ALECAlector, Inc. Common Stock | C | F | C | 14.8x | -82.9% | — | — | $1.84 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Alector, Inc. Common Stock
Alector Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for neurodegeneration. The company's approach focuses on restoring healthy immune function in the brain to counteract underlying pathologies. Its pipeline includes multiple therapeutic candidates, including AL001, AL002, AL003, and AL101.